ADMA is a NOS endogenous inhibitor associated with lung disease (Zakrzewicz and Eickelberg, 2009), whereas SDMA contributes to the NO imbalance by competing with the cationic amino acid transporter-2 for L-arginine uptake (North and Scott, 2011). The gene discussed is NOS2; the disease is lung disorder.